Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new ...

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of ...

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.